We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Novel Mechanism in Childhood Kidney Cancer

Novel Mechanism in Childhood Kidney Cancer

Novel Mechanism in Childhood Kidney Cancer

Novel Mechanism in Childhood Kidney Cancer

In a developing kidney, a mutant reader protein ENL gives rise to tumor-like structures. Credit: Laboratory of Chromatin Biology and Epigenetics at The Rockefeller University
Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Novel Mechanism in Childhood Kidney Cancer"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

As an embryo develops, its cells must learn what to do with the thousands of genes they’ve been equipped with. That’s why each cell comes with a detailed gene-expression manual outlining exactly which genes should be switched on, to what extent, and when.

To execute their respective manuals, the cells employ so-called chromatin reader proteins that identify which gene is up for expression. Now a new study has found that a problem in this gene-regulatory process may cause normal cells to turn malignant and produce Wilms’ tumor, the most common kidney cancer in children.

The findings, published in Nature, open up new treatment possibilities for the disease, which is currently treated by surgery and chemotherapy.

The findings also raise intriguing questions about other cancer types. The researchers found that the implicated reader protein causes problems by acquiring a new property and being too active.

“We have never seen this type of mechanism before,” says Liling Wan, a former postdoctoral associate in the Rockefeller lab of C. David Allis, and now an assistant professor at the University of Pennsylvania. “It raises the question whether this type of molecular mechanism is also hijacked in other cancer types.”

Reading too well

A few years ago, Wan discovered that a reader protein called ENL is involved in the blood cancer leukemia by activating the cancer-causing genes. Her attention was turned to Wilms’ tumor recently, when it was discovered that some people with this cancer carry mutations in the gene that codes for ENL.

To see whether these mutations are indeed involved in the formation of Wilms’ tumor, Wan and her colleagues introduced the mutations to mouse embryonic stem cells, and then instructed the cells to develop all the way into kidneys in a petri dish. “Quite strikingly, when you insert the mutation, you start to see a tumor-like structure appearing in the developing kidney, which resembles what we typically see in human Wilms’ tumor,” Wan says.

The team then took a closer look to understand how mutations in ENL turn these cells into tumor cells. In both the cells that carry the mutation and in unaltered cells, they saw ENL proteins land on the same locations in the genome, suggesting there was nothing wrong with the mutant ENL protein’s ability to recognize which genes should be expressed. The mutant proteins, however, clumped at these sites, causing the genes to be constantly transcribed into RNA, the first steps before turning into proteins.

“This abnormal gene expression confuses the cells as to what they want to become,” Wan says. “Instead of differentiating into mature kidney cells, they start to proliferate more and get stuck in the immature stage, which leads to the formation of a tumor.”

Having discovered this previously unknown mechanism in cancer, Wan and her colleagues are now asking if it might be possible to revert cancer cells back to normal, for instance with drugs that disrupt ENL’s ability to bind to the genome or to form clumps.

“So far we have proof of concept that intervening in any stage of this process can stabilize the gene expression levels and allow the cells to develop normally,” Wan says.

Reference: Wan, et al. (2019) Impaired cell fate through gain-of-function mutations in a chromatin reader. Nature DOI: https://doi.org/10.1038/s41586-019-1842-7

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.